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Abstract
Objective: To evaluate the prevalence of C. difficile infection (CDI) 
among hospitalized patients with toxin-positive stools.
Methods: This study is a multicenter study held in Jordan and focused 
on the prevalence of in-patients with C. difficile toxin-positive diar-
rhea-stools. The study included three hospitals with approximately 
750 beds. In-patients charts, laboratory logbooks for in-patients with 
diarrhea-stool specimens were reviewed. The participating hospitals 
used a rapid test, which detects fecal C. difficile toxins A and B.
Results: 174 stool specimens were reviewed from March 2013 to Oc-
tober 2014, and 170 stool specimens from 168 patients were evalu-
ated. The patients included 102 (60%) males, and 66 (40%) females 
including seven (10.6%) peripartum females. The patients were clas-
sified in the following age groups:neonates ≤ 28 days, infants 29 
days - less than one year old (n = 4, 2.4%), 1 – 4 years (n = 3, 1.8%), 
and arbitrarily: 5 - 9 years (n = 3, 1.8%), 10 – 14 years (n = 3, 1.8%), 
15 – 40 years (n = 33, 19.4%), 41- 64 years, (n = 53, 31.2%) and 
≥ 65 years were (n = 71, 41.8%).Adults and older age groups make 
up the majority of all patients (92.4%). Comorbidities were high-
ly prevalent among the patients: diabetic (n = 71, 41.8%), chronic 
lung diseases (n = 25, 14.7%), solid tumors other than colonic tu-
mors (n = 12, 7.1%), immune-suppressive state (n = 15, 8.8%), and 
one patient had colonic tumor. The majority of the patients (n = 21) 
were on more than one class of broad-spectrum antimicrobials. The 
prevalence of C. difficile toxin-positive stools were 14.63/1000 dis-
charged patients, 12.65% of patients (12.96% of stool specimens) 
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domembraneous colitis, Antibiotic Associated Co-
litis.
Introduction
Clostridium difficile is a Gram-positive 
endospore-forming bacillus that was discovered as 
a bowel colonizer and pathogen in 1935. Healthy 
newborns and infants were found to be colonized 
with C. difficil eat rates ranging from 45 to 70%.
However, the prevalence of toxigenic strains was 
found to be as low as 13%. The colonization rates 
decline as individuals grow older, reaching rates 
lower than 5% in urban-dwelling healthy adults. 
However, colonization rates as high as 25-55% has 
been detected among adult hospitalized patients 
and nursing home residents [1, 2].
The prevalence and pathogenesis of Clostridium 
difficile infection (CDI) was not particularly high until 
the early 1970s and 1980s, when it was evident 
that its rates were rapidly increasing. Over the last 
two decades, the incidence and prevalence of CDI 
has increased markedly in hospital environments, 
where it has acquired greater virulence, exhibited 
higher recurrence rates, and became less 
responsive to metronidazole and resulted in higher 
colectomy rates and mortality. The new strains 
secrete more toxins and are exemplified by North 
American pulsed-field gel electrophoresis type 1 
(NAP1), restriction endonuclease analysis type BI 
(BI), and polymerase chain reaction (PCR) ribotype 
027. The increase in CDI prevalence has become 
so pronounced that it hassuperseded that of 
Staphylococcus spp. infections in some healthcare 
systems [3, 4, 5. 6, 7, 8].
The C. difficile infection incidence and prevalence 
increased markedly with the wide spread of 
antimicrobials, particularly in admitted patients. It 
was initially associated with clindamycin, although 
continued experience with antimicrobials showed 
that other antimicrobials are as likely as clindamycin 
to be correlated with CDI [9]. The prevalence of CDI 
in a nosocomial setting has been surging in North 
American and European hospitals, with estimated 
numbers of 3.82 per 1000 discharges in 2000 and 
8.75 per 1000 discharges in 2008. These increases 
were particularly prominent among patients at 
least 65 years of age [10,11].
Jordan and other Arab countries have few 
published studies on the prevalence of CDI in 
hospital settings. Shehabi et al. performed a study 
at Jordan University Hospital in 2000 and found a 
9.7% prevalence rate of C. difficile isolates or its 
toxin in stools from patients of all ages with diarrhea 
through culture and enzyme immunoassay for the 
detection of C. difficile toxin A. 
and 5.0/1000 patient-day. The age-adjusted CDI distribution showed 
that the rates increased with age and were relatively low in the neo-
natal period.
Conclusion: The hospital-associated C. difficile prevalence showed 
high rates, particularly in adults and older patients, in patients with a 
prolonged hospital stay, and comorbidities.
Keywords: Clostridium difficile Infection, CDI, Toxin A, Toxin B, Pseu-
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Approximately a decade later, Nasereddin et al. 
demonstrated an escalation in CDI rates in the same 
university hospital: the prevalence of toxigenic C. 
difficile isolates were found to be 13.7% among 
adult hospitalized patients, as demonstrated by the 
presence of toxin genes and in association with 
diarrhea [12, 13]. A study conducted in Kuwait 
focused on the PCR ribotyping of environmental 
and ICU clinical strains. A total of 32 different 
ribotypes were detected among the clinical isolates, 
and the predominant toxigenic ribotypes detected 
were types 097 and 078, which are different from 
the findings obtained in North America and Europe, 
which exhibit a dominance of the 027 ribotype [14].
Furthermore, Jordan like most Arab countries 
lack antimicrobial restriction policies and this lack 
may be one reason behind the observed high CDI 
cases, because its prevalence is linked to the misuse 
of antimicrobials [14, 15]. This study underscores 
the importance of studying the CDI prevalence in 
nosocomial settings by shedding light on the limited 
data regarding this evolving problem in Jordan and 
other Arab countries.
Materials and Methods
Settings and Design of Study
This study was a prospective multicenter study 
conducted in Amman, Jordan from March 2013 to 
October 2014 that included three hospitals with 
a total of approximately 750 beds. The study was 
approved by the IRBs in both teaching hospitals 
and by the medical administrator in the community 
hospital.The study focused on the prevalence 
of C. difficile toxin-positive diarrhea stools in in-
patients excluding community-acquired cases. The 
patients’ charts and the laboratory logbooks for 
all in-patients with diarrhea stool specimens were 
reviewed. Several stool tests are available for the 
detection of C. difficile or its toxins [2,16]. However, 
the participating hospitals used the “DUO TOXIN 
A+B-CHECK-1”, an immune-chromatographic 
rapid test that detects both fecal C. difficile toxins 
A and B (VedaLabs, Parcd’Activités du Londeau 
BP 181 – 61006, Alençoncedex, France), with 
excellent sensitivity, specificity, low cost and with 
rapid turnaround time. (http://www.cdc.gov/HAI/
organisms/cdiff/Cdiff_faqs_HCP.html#a7).
Outcome measures
The main outcome measure evaluated in this 
study is the prevalence ofCDI among hospitalized 
patients, as determined through the analysis of 
diarrhea stool toxins. This measure was calculated as 
number of positive CDI patients per 1000 discharged 
patients (a performance quality indicator in some 
healthcare systems). The secondary measures are 
age-adjusted prevalence and the percentage of 
C. difficile toxin-positive stools among clinically 
suspected patients with diarrhea. The definition for 
Clostridium difficile infections was the following: 
the presence of symptoms (usually diarrhea; passage 
of at least three unformed stools in a period of at 
most 24 h), either a stool test result positive for C. 
difficile toxins or toxigenic C. difficile orcolonoscopic 
findings demonstrating pseudomembranous colitis 
(PMC) and a history of treatment with antimicrobial 
or antineoplastic agents within the preceding eight 
weeks. The same previous definition was used to 
diagnose recurrentCDI, and a response to a C. 
difficile infection-specific therapy was considered 
suggestive of diagnosis. The following symptoms, 
signs and laboratory values were utilized in the 
diagnosis of suspected C. difficile infection cases: 
abdominal pains or cramps, lower-quadrant 
tenderness, fever (low grade up to 40.6 °C), 
leukocytosis up to leukemoid reaction, albumin 
< 2.5 gm/dl (protein-losing enteropathy), ileus or 
toxic megacolon and colonic perforation [17].
Statistical analysis
The prevalence of C. difficile toxins in diarrhea 
stools was calculated. The denominator is the 
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number of hospital-discharged patients (positive 
tests per 1000 hospital-discharged patients). Other 
calculations base denominator on the length of 
hospital stay (positive tests per 1000 patient-day) 
and the percentage of patients with diarrhea 
stools (positive tests per diarrhea stool specimens). 
Boxplot analysis was used to clarify the differences 
between CDI-positive and CDI-negative subgroups 
within different age categories as a function of the 
length of hospital stay. Differences with P ≤ 0.05 
were considered statistically significant. One way 
ANOVA for unmatched groups were calculated for 
equality of means. SPSS version 18 was used for 
the data analysis.
Results
A total of 174 patients’s tool specimens were 
reviewed from March 2013 to October 2014;four 
patients were excluded for being outpatients.One 
patient experienced four episodes of diarrhea, 
and one patient experienced two relapse episodes 
during a prolonged hospital stay. In total, 174 stool 
specimens from 168 patients were evaluated. The 
patients included 102 (60%) males and 66 (40%) 
females including 7 (10.6%) peripartum females. 
The patients were classified in the following age 
groups: neonates ≤ 28 days, infants 29 days-less 
than one year old (n = 4, 2.4%), 1 – 4 years (n = 
3, 1.8%), and arbitrarily: 5 – 9 years (n = 3, 1.8%), 
10 – 14 years (n = 3, 1.8%), 15 – 40 years (n = 33, 
19.4%), 41- 64 years, (n = 53, 31.2%) and ≥65 
years were (n = 71, 41.8%). Adults and older age 
groups make up the majority of all patients (92.4%). 
Comorbidities were highly prevalent among the 
patients: diabetic (n = 71, 41.8%), chronic lung 
diseases (n = 25, 14.7%), solid tumors other than 
colonic tumors (n = 12, 7.1%), immune-suppressive 
state (n = 15, 8.8%), and one patient had colonic 
tumor. The majority of the patients (n =21) were 
on more than one class of antimicrobial, which 
were mostly broad-spectrum agents: carbapenems 
were prescribed to (n = 13, 61.9%) of the patients, 
quinolones were administered to (n = 12, 57.1%) 
of the patients, cephalosporins was prescribed to 
(n = 4, 19%) of the patients, glycopeptides were 
prescribed to (n = 4, 19%) of the patients, and 
β-lactam β-lactamases inhibitors were administered 
to (n = 7, 33.3%) of the patients. Details on the 
prescribed antimicrobials are presented in (Table 1). 
The prevalence of C. difficile toxin-positive stools in 
the patients were 14.63/1000 discharged patients, 
12.65% of patients (12.96% of stool specimens) 
and 5.0/1000 patient-hospital day (Table 2). The 
age-adjustedCDI distribution among the categories 
showed that the rates exhibited a polynomial trend: 
the rates increased with age and were relatively 
low during the neonatal period due to a noticeable 
absence of C. difficile infection in patients between 
1 and 14 years of age (Figure 1). However, the 15-40 
age categories showed the highest positive correlation 
of CDI with the length of hospital stay, followed by 
the 41-64 and ≥65 categories (Figure 2).
Discussion
In our study, although sample number was 
modest, the results demonstrated that the C. 
difficile toxin rates in clinical specimens from 
patients suspected to have CDI according a pre-
set definition were not different from the rates 
reported from other parts of the world. The CDI 
prevalence was calculated by several denominators 
in different studies. Prevalence of 14.63/1000 
discharged patients and 5/1000 patient-days were 
in our study (Table 2). In recent studies in Britain, 
the rates were found to be 2.16/1,000 patient-
days [18]. In other studies, higher rates were found 
among older age groups [10, 11]. The comparison 
of our current data with other local data published 
by Shehabi et al, who found that 9.7% of diarrhea 
stools from clinical specimens to be positive for a 
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Table 1.  Characteristics of 168 patients included in the Prevalence of Nosocomial Clostridium difficile 
infections from whom 174 stool specimen were submitted.
Characteristic Number (%)
Age (years)#: ≤ 28 days
29 days < 1
1 - 4
5 - 9
10 – 14
15- 40
41- 64
≥ 65
0.0
4 (2.4)
3 (1.8)
3 (1.8)
3 (1.8)
33 (19.4)
53 (31.2)
71 (41.8)
Gender Male
 Female
 Peripartum females
102 (60)
  66 (40)
    7/66 (10.6)
Co-Morbidity
Diabetes mellitus
B. asthma/COPD
CHF
CVA
Sepsis/Bacteremia
Solid tumour
Immunosuppression
Hematological Malignancy
Colonic tumour
Others*
71 (41.8)
25 (14.7)
26 (15.3)
26 (15.3)
24 (14.1)
12 (7.1)
10 (5.9)
  5 (2.9)
  2 (1.2)
101(55.4)
Antimicrobials** used by C. difficile infected patients within 8 
weeks of presentation 
C. difficile-toxin positive stools/total positive counts (N 
= 21, and%)&
Quinolones
Cephalosporines
Carbapenems
Penicillins
β-lactams, β-lactamsase inhibitor
Glycopeptides
Colistin
Tigecycline
12 (57.1)
4 (19)
13 (61.9)
1 (4.8)
7 (33.3)
6 (28.6)
4(19)
2 (9.5)
2 (9.5)
&: Aminoglycosides, clindamycin, sulpha, linezolid, antifungal and antineoplastic each equals 0.0 
*Other Comorbidities/presenting diagnoses: mostly coronary heart diseases and hypertension. Trauma (7), CAUTI/UTI (1), CLABSI 1, SSTI (2), 
Abdominal sepsis 
(3), Meningitis (1) and renal Failure.
** Multivariate testes of in between anti-infective agents for causation of CDI (P > .05)
#Total numbers in this box (174) refers to the number of stools specimen for the 168 patients.
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C. difficile toxin, revealed that our data paralleled 
the denominator and methodology of the previous 
study. The present study showed that 12.96% of 
suspected patients with diarrhea were positive, 
showing an increase over the last 12 years of 
3.26% (P< 0.0001) both patient populations 
originated from the same geographic area [12]. 
This finding demonstrates that rates in Jordan are 
incerased over time at a rate similar to that observed 
worldwide [20]. ThoughC. difficile infection has 
exhibitedanincrease in the last few years, this 
may still be consideredanunderestimation due to 
limitations of hospital’ surveillance, as some of 
these cases are discharged to community without 
being capturedby healthcare systems [21].
The prevalence of nosocomial CDI was 
demonstrated to be related to the time of hospital 
stay. Earlier studies showed that this prevalence 
is associated with the length of ICU stay [22], 
Figure 1. C. difficile infection distribution ratios (C. difficile-Toxin positive-patients) according to different age groups, with polynomial trend 
line. CDI: Clostridium difficile infection. C. difficile Toxin-positive patients (toxin-positive age groups were included in analysis): F = 0.61, P = 
0.64, by ANOVA. Total C. difficile infection(N = 21); age group ≥ 65 (n = 8), 41 – 64 (n = 9), 15 – 40 (n = 3) and (n = 1) positiveC. difficile 
infection in 29 days – 1 year group.
Table 2.  The prevalence of CDI among suspected 
hospitalized 168 patients with 174 stool 
specimens**, the estimations were 
based on detection of toxins A, B or both 
in stools$ specimen.
C. difficle-Toxin positive stools per: Rates
1000 Discharged Patients* 14.63
Patients with diarrhoea 12.65%
Submitted stool specimens 12.96%
1000 Patient-days  5.0
*Outcome measure.
CDI: Clostridium difficile infection
$ 95.3% were diarrhoea stools according to the definition in the 
text (Materials and methods).
**One patient with prolonged hospital stay submitted 4 specimens 
and one submitted two specimens.
This article is available from: www.iajaa.org   /   www.medbrary.com
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Figure 2. Boxplot representation of 
the patients with C. difficile infection 
distributed according to length of 
hospital stay (Y-axis), and different age 
groups (X-axis) clustered in pairs as 
positive and negative C. difficile-toxin. 
CDI: Clostridium difficile infection. 
Open circle: Moderate outliers. Stars: 
Extreme outliers. P > 0.05 for within 
age groups, and among age groups, 
significance was analyzed by ANOVA.
because nosocomial transmission often occurs in 
this setting due to the occasional break in infection 
control practices and the increased prescription of 
antimicrobials [10,23].
The patients in this study exhibited high rates of 
co-morbidities, and the results were skewed toward 
adults andolder population (92.4%) and included a 
minority of pediatric patients. The results showed a 
relative increase in the neonatal period (Figure 2). 
Co-morbidities were prevalentand38.2% of the 
patients were on steroids for different reasons. In 
addition, many of the patients were suffering from 
chronic lung diseases, were on immunosuppressive 
therapy and had solid tumors. .Moreover, 41.8% 
of the patients were diabetic, apatient population 
that is expected to stay longer in the hospital, 
which places them at a higher risk for nosocomial 
C. difficile infection acquisition, not including the 
prolongation of their hospital stay due to C. difficile 
infection [22].
In conclusion, our study employed an immune-
chromatographic rapid assay test to demonstrate 
that C. difficile infection prevalence in Jordan is 
not different from that found in other parts of 
the world. The development of other methods for 
Clostridium difficile identification, such as PFGE, 
restriction endonuclease analysis, EIA and PCR, is 
needed to help clinicians avoid overlooking cases 
that may escape detection through the immune-
chromatographic rapid assay test [24], and novel 
surveillance methodologies to include unaccounted 
discharged patients [21]. Of note, none of our 
patients had a perforated colon, severe toxemia, 
bleeding or a toxic megacolon. This study focused 
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on the hospital-associated CDI. Data on community-
associated CDI is sparse and hope fully in near future 
a plan for a studyby this group will be implemented 
to assess the prevalence of the community-
associated CDI, which will increase the detection of 
the outpatient CDI without undue delay. Specially, 
CDI, a potentially serious illness, may occur in a 
population without the traditional risk factors but 
share the degree of severity [25, 26].
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